Inflammation in the setting of chronic allograft dysfunction post-kidney transplant: Phenotype and genotype

Clinical Transplantation

Volumn 27, Issue 3, 2013, Pages 348-358

  Israni, Ajay K ^a   Leduc, Robert ^a   Jacobson, Pamala A ^a   Wildebush, Winston ^a   Guan, Weihua ^a   Schladt, David ^a   Matas, Arthur J ^b   Oetting, William S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Chronic allograft dysfunction; Single nucleotide polymorphisms

Indexed keywords

CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; DIMETHYLANILINE MONOOXYGENASE (N-OXIDE FORMING); OXYGENASE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHRONIC ALLOGRAFT DYSFUNCTION; CREATININE BLOOD LEVEL; DIALYSIS; DISEASE SEVERITY; DRUG METABOLISM; FEMALE; GENOTYPE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; PHENOTYPE; PLASMAPHERESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL GRAFT DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ALLOGRAFT; CHRONIC DISEASE; COMPLICATION; FOLLOW UP; GENETICS; GRAFT REJECTION; GRAFT SURVIVAL; INFLAMMATION; KIDNEY DISEASES; MIDDLE AGED; PATHOLOGY; PRIMARY GRAFT DYSFUNCTION; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

ADULT; ALLOGRAFTS; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INFLAMMATION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OXYGENASES; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRIMARY GRAFT DYSFUNCTION; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84878639465     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12074     Document Type: Article

References (40)

1. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003: 349: 2326.
2. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008: 8: 753.
3. Kasiske BL, Heim-Duthoy KL, Tortorice K, Rao KV. The variable nature of chronic declines in renal allograft function. Transplantation 1991: 51: 330.
4. Brown KM, Kondeatis E, Vaughan RW et al. Influence of donor C3 allotype on late renal-transplantation outcome. [see comment]. N Engl J Med 2006: 354: 2014.
5. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006: 314: 1461.
6. Klein R, Zeiss C, Chew EY. Complement factor H polymorphism in age-related macular degeneration. Science 2005: 308: 385.
7. Jacobson P, Oetting WS, Brearley AM et al., for DeKAF investigators. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation 2011: 91: 300.
8. Jacobson P, Schladt D, Oetting WS et al., for the DEKAF investigators. Genetic determinants of mycophenolate related anemia and leukopenia following transplantation. Transplantation 2011: 91: 309.
9. Jacobson PA, Schladt D, Israni A et al. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. Transplantation 2012: 93: 624.
10. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol 2011: 72: 948.
11. Kasiske B, Gaston R, Gourishankar S et al. Long-term deterioration of kidney allograft function. Am J Transplant 2005: 5: 1405.
12. Israni A, Leduc R, Holmes J et al. Single nucleotide polymorphisms, acute rejection and severity of tubulitis in kidney transplantation, accounting for center-to-center variation. Transplantation 2010: 90: 1401.
13. Van Ness B, Ramos C, Haznadar M et al. Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med 2008: 6: 26.
14. Hardenbol PBJ, Jain M, Nilsson M, Namsaraev EA, Karlin-Neumann GA et al. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol 2003: 21: 673.
15. Cox DR. Regression models and life-tables. J R Stat Soc 1972: 34: 187.
16. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994: 81: 515.
17. Akkina SK, Connaire JJ, Israni AK, Snyder JJ, Matas AJ, Kasiske BL. Similar outcomes with different rates of delayed graft function may reflect center practice, not center performance. Am J Transplant 2009: 20: 1351.
18. Hines RN, Hopp KA, Franco J, Saeian K, Begun FP. Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase. Mol Pharmacol 2002: 62: 320.
19. Hernandez D, Janmohamed A, Chandan P, Phillips IR, Shephard EA. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 2004: 14: 117.
20. Grimm PC, Nickerson P, Gough J et al. Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 2003: 14: 1662.
21. El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009: 9: 527.
22. Matas AJ, Leduc R, Rush D et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study. Am J Transplant 2010: 10:315.
23. Park WD, Griffin MD, Cornell LD et al. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010: 21:1987.
24. Hisamuddin IM, Yang VW. Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives. Pharmacogenomics 2007: 8: 635.
25. Hines RN, Hopp KA, Franco J, Saeian K, Begun FP. Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase. Mol Pharmacol 2002: 62: 320.
26. Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK Jr, Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos 2010: 38: 25.
27. Parte P, Kupfer D. Cyclic oxidation by human FMO1 and FMO3 of tamoxifen to tam-N-oxide and its reduction back to tamoxifen by human P450s: model cyclic reactions for novel triphenylethyleneamine SERMs. Drug Metab Dispos 2005: 33: 1446.
28. Zhang F, Saha S, Shabalina SA et al. Differential arginylation of actin isoforms is regulated by coding sequence-dependent degradation. Science 2010: 329:1534.
29. Ouyang S, He F. Phylogeny of a growth hormone-like cytokine superfamily based upon 3D structure. J Mol Evol 2003: 56: 131.
30. Anderson PD, Mehta NN, Wolfe ML et al. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab 2007: 92: 2272.
31. De Rosa V, Procaccini C, Cali G et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007: 26: 241.
32. Lago F, Dieguez C, Gomez-Reino J et al. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007: 18: 313.
33. Lord GM, Lord GM. Leptin as a proinflammatory cytokine. Contrib Nephrol 2006: 151: 151.
34. Takahashi H, Honma M, Ishida-Yamamoto A et al. Adiponectin and leptin modulate cell proliferation and cytokine secretion of normal human keratinocytes and T lymphocytes. J Dermatol Sci 2010: 59:143.
35. Dhar M, Sepkovic DW, Hirani V et al. Omega oxidation of 3-hydroxy fatty acids by the human CYP4F gene subfamily enzyme CYP4F11. J Lipid Res 2008: 49: 612.
36. Azarpira N, Bagheri M, Raisjalali GA et al. Angiotensinogen, angiotensin converting enzyme and plasminogen activator inhibitor-1 gene polymorphism in chronic allograft dysfunction. Mol Biol Rep 2009: 36: 909, PMID: 18454324.
37. Satoh S, Saito M, Inoue K et al. Association of cytokine polymorphisms with subclinical progressive chronic allograft nephropathy in Japanese renal transplant recipients: preliminary study. Int J Urol 2007: 14: 990.
38. ViklickÝ OHJ, Kvasnicka J, Matl I et al. Association of methylenetetrahydrofolate reductase T677 allele with early development of chronic allograft nephropathy. Clin Biochem 2004: 37: 919, PMID: 15369724.
39. Nikolova PN, Ivanova MI, Mihailova SM et al. Cytokine gene polymorphism in kidney transplantation-impact of TGF-beta 1, TNF-alpha and IL-6 on graft outcome. Transpl Immunol 2008: 18: 344.
40. Mannon RB, Matas AJ, Grande J et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant 2011: 10: 2066.